Former type
|
Subsidiary |
---|---|
Traded as | NASDAQ: ARIA |
Industry | Pharmaceuticals, biotechnology |
Fate | Merged with Takeda Pharmaceuticals |
Founded | 1991 |
Defunct | 2017 |
Headquarters | Cambridge, MA, United States |
Key people
|
Harvey Berger (CEO) Alex Denner, Chairman of the Board Harvey Berger, retired (as of December 2015) Chairman & CEO Timothy P. Clackson, President of Research and Development and Chief Scientific Officer |
Products | Ridaforolimus (Under development) Ponatinib (FDA approved, trade name Iclusig) Brigatinib (Under development) |
Revenue | US$178.98M (FY 2010) |
Operating income
|
US$104.90M (FY 2010) |
Net income
|
US$85.25M (FY 2010) |
Total assets | US$50.4M (FY 2010) |
Number of employees
|
125 (2011) |
Website | www.ariad.com |
ARIAD Pharmaceuticals, Inc. was an American oncology company founded in 1991 and headquartered in Cambridge, Massachusetts. On February 16, 2017, Takeda announced it had completed its acquisition of Ariad.
On December 14, 2012 the FDA approved Ariad Pharmaceutical's leukemia drug Iclusig for patients with all forms of chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant or unable to tolerate other tyrosine kinase therapies on the market. The drug was temporarily withdrawn from the market in November 2013 "because of the risk of life-threatening blood clots and severe narrowing of blood vessels". This suspension was partially lifted on December 20, 2013 with ponatinib being issued revised prescribing information, a new "black box warning" and a "Risk Evaluation and Mitigation Strategy" in place to better evaluate the risks and benefits of using the drug.
Ariad also has brigatinib, a lung cancer drug which has completed its registration trial in ALK fusion driven non-small cell lung cancer as of June 2016.
In January 2017, Takeda announced it would acquire Ariad for $5.2 billion, expanding the company's oncology and hematology divisions. The acquisition was completed on February 16, 2017.
Ariad is engaged in the discovery, development, and commercialization of medicines for cancer patients. It offers Iclusig (ponatinib), a tyrosine kinase inhibitor for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States and Europe. Various investigator-sponsored trials are ongoing in several indications, including first line and second line CML, acute lymphoblastic leukemia (BCR-ABL), acute myeloid leukemia (FLT3 inhibitor), non-small cell lung cancer (RET, FGFR), advanced biliary cancer With FGFR2 fusions and other cancers with activating mutations involving the following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, and KIT.
In addition, its product pipeline consists of Brigatinib, an investigational inhibitor of anaplastic lymphoma kinase for treating advanced solid tumors comprising non-small cell lung cancer. This drug reported results of its registration trial at ASCO, June 6, 2016, with encouraging results; AP32788, an inhibitor of solid tumors with EGFR and HER2 activating mutation, which began phase I testing in the second quarter of 2016; and Ridaforolimus, an investigational mTOR inhibitor for various types of cancers. The company sells and markets Iclusig through specialty pharmacies and specialty distributors in the United States. It has collaboration and license agreement with Medinol Ltd. and ICON Medical Corp. to develop and commercialize stents and other medical devices to deliver ridaforolimus.
On February 21, 2014 Ariad Pharmaceuticals announced the appointment of Sarissa Capital's Alexander J. Denner, Ph.D. to a two-year term on the company's Board of Directors. Previously, Denner served as a senior managing director at Carl Icahn's Icahn Capital and is currently Ariad's second-largest shareholder. On January 10, 2016, Ariad announced that Denner had become the chairman of the board, replacing Harvey Berger. Shortly thereafter, the company announced the termination of its shareholder's rights plan (the "poison pill.")
In July 2015, the company announced it was due to receive up to $200 million through a royalty financing deal with PDL BioPharma on future sales of ponatinib.
In 2016, the company was ranked #3 on the Deloitte Fast 500 North America list.
2016-06-22 | Reiterated Rating | Jefferies Group | Buy | $13.00 |
2016-06-21 | Reiterated Rating | Cowen and Company | Outperform | $10.00 |
2016-06-20 | Reiterated Rating | RBC Capital | Hold | |
2016-06-20 | Reiterated Rating | Royal Bank Of Canada | Hold | |
2016-06-06 | Reiterated Rating | JMP Securities | Buy | |
2016-06-06 | Reiterated Rating | Cowen and Company | Buy | $10.00 |
2016-05-24 | Reiterated Rating | William Blair | Buy | $10.00 |
2016-05-24 | Reiterated Rating | Jefferies Group | Buy | $13.00 |
2016-05-19 | Reiterated Rating | Cowen and Company | Outperform | $10.00 |
2016-05-12 | Reiterated Rating | Barclays | Sell | |
2016-05-12 | Reiterated Rating | Barclays PLC | Sell | |
2016-05-11 | Boost Price Target | Barclays | Underweight | $6.00 to $8.00 |
2016-05-05 | Upgrade | Cowen and Company | Market Perform to Outperform | $10.00 |
2016-04-19 | Reiterated Rating | JMP Securities | Outperform | $9.00 |
2016-04-17 | Reiterated Rating | Cowen and Company | Hold | |
2016-03-11 | Reiterated Rating | JPMorgan Chase & Co. | Outperform | $11.00 to $9.00 |
2016-03-09 | Boost Price Target | JPMorgan Chase & Co. | Market Outperform | $9.00 to $11.00 |
2016-03-09 | Lower Price Target | JMP Securities | Market Outperform | $11.00 to $9.00 |
2016-02-25 | Reiterated Rating | RBC Capital | Hold | |
2016-02-22 | Lower Price Target | Goldman Sachs | $7.00 to $5.00 | |
2016-02-22 | Lower Price Target | Goldman Sachs Group Inc. | $7.00 to $5.00 | |
2016-01-19 | Initiated Coverage | Barclays | Underweight | $6.00 to $6.00 |
2015-08-07 | Reiterated Rating | JPMorgan Chase & Co. | Neutral | $8.00 to $9.00 |
2015-07-21 | Reiterated Rating | Cowen and Company | Market Perform | |
2015-07-20 | Boost Price Target | Goldman Sachs | Neutral | $6.00 to $7.00 |
2015-06-26 | Reiterated Rating | William Blair | Outperform | $11.00 |
2015-06-06 | Reiterated Rating | William Blair | Outperform | $11.00 |
2015-06-05 | Reiterated Rating | HC Wainwright | Buy | |
2015-05-16 | Reiterated Rating | BMO Capital Markets | Outperform | $14.00 |
2015-05-16 | Reiterated Rating | Stifel Nicolaus | Buy | |
2015-05-10 | Initiated Coverage | JPMorgan Chase & Co. | Neutral | $8.00 |
2015-04-20 | Set Price Target | BMO Capital Markets | Buy | $14.00 |
2015-02-23 | Set Price Target | HC Wainwright | Buy | $10.00 |
2015-01-07 | Set Price Target | HC Wainwright | Buy | $8.00 |
2014-12-11 | Downgrade | Credit Suisse | Neutral to Underperform | $8.00 to $6.00 |
2014-12-11 | Downgrade | Credit Suisse Group AG | Neutral to Underperform | $8.00 to $6.00 |
2014-11-06 | Reiterated Rating | Chardan Capital | Neutral | |
2014-08-08 | Reiterated Rating | Citigroup Inc. | Sell | $7.00 to $5.00 |
2014-08-07 | Lower Price Target | JMP Securities | Market Outperform | $8.00 to $7.00 |
2014-08-07 | Reiterated Rating | Chardan Capital | Buy | |
2014-06-02 | Reiterated Rating | Jefferies Group | Positive | |
2014-05-08 | Reiterated Rating | JMP Securities | Market Outperform | $10.00 to $8.00 |
2014-05-05 | Upgrade | Jefferies Group | Hold to Buy | $8.00 to $14.00 |
2014-03-26 | Reiterated Rating | BMO Capital Markets | Positive | |
2014-03-25 | Initiated Coverage | HC Wainwright | Neutral to Buy | $14.00 |
2014-02-27 | Reiterated Rating | Goldman Sachs | Hold to Neutral | |
2014-02-26 | Upgrade | Maxim Group | Hold to Buy | $11.00 |
2014-02-26 | Downgrade | Chardan Capital Markets | Buy to Neutral | |
2014-02-26 | Boost Price Target | Citigroup Inc. | $5.50 to $7.00 | |
2014-02-26 | Downgrade | Chardan Capital | Buy to Neutral | $9.00 |
2014-02-26 | Boost Price Target | Jefferies Group | $7.00 to $8.00 | |
2014-02-07 | Set Price Target | Credit Suisse | $5.00 to $8.00 | |
2014-01-24 | Upgrade | BMO Capital Markets | Market Perform to Outperform | $8.00 to $14.00 |
2014-01-13 | Reiterated Rating | JMP Securities | Outperform | $10.00 |
2014-01-06 | Downgrade | Citigroup Inc. | Neutral to Sell | $2.50 to $5.50 |
2013-12-23 | Upgrade | Chardan Capital Markets | Neutral to Buy | $9 |
2013-12-23 | Reiterated Rating | Bank of America | Underperform | $2.00 to $3.00 |
2013-12-23 | Reiterated Rating | Credit Suisse | Buy to Neutral | $2.50 to $5.00 |
2013-12-23 | Upgrade | Chardan Capital | Neutral to Buy | $9.00 |
2013-12-23 | Upgrade | William Blair | Market Perform to Outperform | $3.00 to $12.00 |
2013-12-20 | Boost Price Target | Guggenheim | Neutral | $3.00 to $6.00 |
2013-12-20 | Boost Price Target | Cowen and Company | Market Perform | $2.50 to $4.00 |
2013-12-20 | Upgrade | JMP Securities | Market Perform to Outperform | $10.00 |
2013-12-20 | Boost Price Target | BMO Capital Markets | Market Perform | $4.00 to $8.00 |
2013-12-10 | Upgrade | Stifel | Hold to Buy | $7 |
2013-12-10 | Upgrade | Stifel Nicolaus | Hold to Buy | $7.00 |
2013-11-12 | Reiterated Rating | Goldman Sachs | Neutral | |
2013-11-01 | Lower Price Target | Credit Suisse | Neutral | $4.00 to $2.50 |
2013-11-01 | Lower Price Target | BMO Capital Markets | $8.00 to $2.50 | |
2013-11-01 | Downgrade | Leerink Swann | Outperform to Market Perform | $7.00 to $2.50 |
2013-11-01 | Downgrade | Jefferies Group | Buy to Hold | $7.00 to $2.50 |
2013-10-31 | Downgrade | Cowen and Company | Outperform to Market Perform | $10.00 to $2.50 |
2013-10-31 | Downgrade | Guggenheim | Buy to Neutral | $7.00 to $3.00 |
2013-10-23 | Downgrade | Lazard Capital Markets | Buy to Neutral | |
2013-10-21 | Downgrade | HC Wainwright | Buy to Neutral | $2.50 |
2013-10-21 | Reiterated Rating | Jefferies Group | Buy | $7.00 |
2013-10-21 | Downgrade | Oppenheimer | Outperform to Market Perform | $7.00 |
2013-10-21 | Downgrade | William Blair | Outperform to Market Perform | |
2013-10-18 | Lower Price Target | Guggenheim | Buy | $10.00 to $7.00 |
2013-10-18 | Downgrade | RBC Capital | Outperform to Sector Perform | $9.00 to $4.00 |
2013-10-18 | Downgrade | JPMorgan Chase & Co. | Overweight to Neutral | |
2013-10-14 | Downgrade | Argus | Hold to Sell | |
2013-10-11 | Lower Price Target | Credit Suisse | Neutral | $20.00 to $6.00 |
2013-10-10 | Lower Price Target | Oppenheimer | Outperform | $24.00 to $7.00 |
2013-10-10 | Downgrade | Summer Street Research | Buy to Neutral | |
2013-10-10 | Downgrade | Chardan Capital Markets | Buy to Neutral | |
2013-10-10 | Downgrade | Barclays | Overweight to Underweight | $25.00 to $4.00 |
2013-10-10 | Lower Price Target | William Blair | Outperform | $26.00 to $7.00 |
2013-10-10 | Lower Price Target | RBC Capital | Outperform | $28.00 to $9.00 |
2013-10-10 | Lower Price Target | Guggenheim | Buy | $28.00 to $10.00 |
2013-10-10 | Lower Price Target | Leerink Swann | Outperform | $28.00 to $9.00 |
2013-10-10 | Downgrade | Summer Street | Buy to Neutral | |
2013-10-10 | Downgrade | Chardan Capital | Buy to Neutral | $26.00 |
2013-10-10 | Downgrade | Citigroup Inc. | Buy to Neutral | |
2013-10-10 | Downgrade | JMP Securities | Outperform to Market Perform | |
2013-10-09 | Lower Price Target | Jefferies Group | Buy | $23.00 to $7.00 |
2013-10-09 | Lower Price Target | Cowen and Company | Hold | $27.50 to $10.00 |
2013-10-09 | Lower Price Target | BMO Capital Markets | Market Perform | $21.00 to $8.00 |
2013-10-09 | Downgrade | Maxim Group | Buy to Hold | $24.00 |
2013-10-09 | Downgrade | Bank of America | Buy to Neutral | $24.00 to $7.00 |
2013-10-09 | Downgrade | Brean Capital | Buy to Hold | |
2013-10-09 | Downgrade | Stifel Nicolaus | Buy to Hold | |
2013-09-30 | Upgrade | Oppenheimer | Market Perform to Outperform | $23.00 to $24.00 |
2013-09-30 | Lower Price Target | JMP Securities | Market Outperform | $30.00 |
2013-09-30 | Lower Price Target | Brean Capital | Buy | $28.00 to $26.00 |
2013-09-30 | Lower Price Target | Maxim Group | Buy | $26.00 to $24.00 |
2013-09-30 | Downgrade | BMO Capital Markets | Outperform to Market Perform | $37.00 to $21.00 |
2013-09-18 | Boost Price Target | Goldman Sachs | $20.00 to $21.00 | |
2013-09-04 | Initiated | Chardan Capital Markets | Buy | $28 |
2013-02-26 | Reiterated | Barclays | Overweight | $30 to $29 |
2016-06-22 | Reiterated Rating | Jefferies Group | Buy | $13.00 |
2016-06-21 | Reiterated Rating | Cowen and Company | Outperform | $10.00 |
2016-06-20 | Reiterated Rating | RBC Capital | Hold | |
2016-06-20 | Reiterated Rating | Royal Bank Of Canada | Hold | |
2016-06-06 | Reiterated Rating | JMP Securities | Buy |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In ARIA 12 funds of 2213 total. Show all
Fund name | Ticker shares |
---|---|
BlackRock Fund Advisors | 8.96M |
BlackRock Institutional Trust Company, N.A. | 4.86M |
BlackRock Investment Management, LLC | 0.67M |
Adamant Biomedical Investments AG | 0.30M |
BLACKROCK ADVISORS LLC | 0.20M |
Geduld E E | 0.19M |
BlackRock Group LTD | 0.17M |
EverPoint Asset Management, LLC | 45000 |
CITY NATIONAL BANK | 30280 |
Apex Capital Management | 14489 |
MetLife Securities, Inc | 13088 |
BlackRock Japan Co. Ltd | 1769 |
Name Relationship | Total Shares | Holding stocks |
---|---|---|
BERGER HARVEY J M D Chairman & CEO | 0.93% (1732111) | ARIA / |
LAMARCHE JAY R | 0.30% (552205) | ARIA / |
FITZGERALD EDWARD M Executive VP, CFO | 0.17% (320367) | ARIA / |
BERSTEIN DAVID L Senior VP, Chief IP Officer | 0.14% (262115) | ARIA / |
Haluska Frank SVP, Clinical R&D, CMO | 0.08% (158711) | ARIA / |
Cantor Maria E SVP, Corporate Affairs | 0.08% (144667) | ARIA / QURE / |
LAVIDAS ATHANESE | 0.07% (131631) | ARIA / |
WILSON WAYNE | 0.06% (113000) | ARIA / CNSL / EDGW / FRP / HOLX / |
Radaelli Massimo | 0.06% (105500) | ARIA / NBY / |
Duvall Martin J SVP, Commercial Operations | 0.06% (105189) | ARIA / TOCA / |
DODION PIERRE F SVP, Corp. Dev. & Operations | 0.05% (102532) | ARIA / |
Keane Raymond T SVP General Counsel & CCO | 0.03% (62096) | ARIA / |
Whelan, Jr. Robert M. | 0.02% (44859) | ARIA / AZPN / |
DesRosier Thomas EVP, General Counsel | 0.02% (36630) | ARIA / CBST / |